X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (64) 64
humans (55) 55
obesity (39) 39
male (35) 35
female (33) 33
endocrinology & metabolism (30) 30
middle aged (28) 28
adult (26) 26
diabetes (23) 23
type 2 diabetes (22) 22
aged (16) 16
diabetes mellitus, type 2 - drug therapy (15) 15
analysis (14) 14
insulin (14) 14
risk factors (14) 14
abridged index medicus (12) 12
double-blind method (12) 12
drug therapy (12) 12
medicine, general & internal (12) 12
animals (11) 11
blood glucose - metabolism (11) 11
glucose (11) 11
health aspects (11) 11
hypoglycemic agents - therapeutic use (11) 11
weight control (11) 11
clinical trials (10) 10
double-blind (10) 10
insulin - blood (10) 10
insulin-resistance (10) 10
internal medicine (10) 10
body mass index (9) 9
diabetes mellitus (9) 9
insulin resistance (9) 9
mortality (9) 9
pharmacology & pharmacy (9) 9
research (9) 9
treatment outcome (9) 9
exercise (8) 8
glycemic control (8) 8
hypothalamus (8) 8
leptin (8) 8
physiological aspects (8) 8
rats (8) 8
type 2 diabetes mellitus (8) 8
weight loss (8) 8
body weight (7) 7
body-weight (7) 7
care and treatment (7) 7
dapagliflozin (7) 7
dextrose (7) 7
diabetes mellitus, type 2 - blood (7) 7
diabetes mellitus, type 2 - metabolism (7) 7
diet (7) 7
inadequate glycemic control (7) 7
medicine (7) 7
mellitus (7) 7
obstructive sleep apnoea (7) 7
adolescent (6) 6
beta-cell function (6) 6
cardiac & cardiovascular systems (6) 6
case-control studies (6) 6
complications and side effects (6) 6
diabetes mellitus, type 2 - physiopathology (6) 6
endocrinology (6) 6
ghrelin (6) 6
glucosides - therapeutic use (6) 6
hypoglycemic agents (6) 6
hypoglycemic agents - adverse effects (6) 6
management (6) 6
nutrition & dietetics (6) 6
obesity - complications (6) 6
quality of life (6) 6
weight loss - drug effects (6) 6
weight-loss (6) 6
adults (5) 5
aged, 80 and over (5) 5
blood glucose - drug effects (5) 5
blood pressure (5) 5
canagliflozin (5) 5
cardiovascular-disease (5) 5
cross-over studies (5) 5
diagnosis (5) 5
dose-response relationship, drug (5) 5
efficacy (5) 5
food (5) 5
gastrointestinal transit (5) 5
glucose metabolism (5) 5
glucosides - adverse effects (5) 5
hypoglycemic agents - administration & dosage (5) 5
inflammation (5) 5
metabolic diseases (5) 5
metabolic syndrome (5) 5
metformin (5) 5
obesity - metabolism (5) 5
obesity - physiopathology (5) 5
original (5) 5
sodium-glucose transporter 2 - antagonists & inhibitors (5) 5
therapy (5) 5
young adult (5) 5
anti-obesity agents - therapeutic use (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Internal Medicine, ISSN 0003-4819, 03/2012, Volume 156, Issue 6, pp. 405 - 415
Background: Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the... 
Primary funding source: astrazeneca and bristol-myers squibb | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | THERAPY | DOUBLE-BLIND | RISK | GLIMEPIRIDE | INADEQUATE GLYCEMIC CONTROL | Index Medicus | Abridged Index Medicus
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 09/2018, Volume 503, Issue 2, p. 1049
Metaflammation in adipose tissue, which is characterized by increased local gene expression and secretion of pro-inflammatory factors, may contribute to the... 
Vitamin D | Interleukins | RNA | Genes | Chronic diseases | Calcifediol | Interferon | Alfacalcidol | T cells | Methylation | Biological response modifiers | Genetic translation
Journal Article
Diabetes Research and Clinical Practice, ISSN 0168-8227, 09/2019, Volume 155, pp. 107791 - 107791
Early treatment intensification for type 2 diabetes mellitus (T2DM) is often required to achieve glycaemic control and avoid longer-term complications. We... 
Treatment intensification | T2DM | Type 2 diabetes mellitus | Early treatment | Dapagliflozin | Clinical Practice Research Datalink | Index Medicus
Journal Article
Diabetology and Metabolic Syndrome, ISSN 1758-5996, 01/2019, Volume 11, Issue 1, p. 9
Metabolic syndrome is characterized by macrophage infiltration and inflammatory responses-metaflammation in adipose tissue. IL-6 and IL-1β could mediate the... 
Inflammatory responses | Human white preadipocytes | D | 1α,25(OH) | p44/42 MAPK | IL-1β | Macrophages | relA | IL-6
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 1, pp. 11 - 22
Journal Article
Journal of Diabetes and Its Complications, ISSN 1056-8727, 04/2015, Volume 29, Issue 3, p. 438
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, has demonstrated glycemic improvements across studies of patients with type 2 diabetes mellitus... 
Type 2 diabetes | Glucose | Dextrose
Journal Article
Journal Article
Medicine, ISSN 1357-3039, 2014, Volume 43, Issue 2, pp. 73 - 76
Abstract Obesity develops when cumulative energy intake exceeds energy expenditure. The biological processes regulating energy balance are highly regulated.... 
Internal Medicine | Appetite | satiety | ghrelin | genetics | pro-opiomelanocortin | metabolic rate | Prader–Willi syndrome | leptin | hypothalamus | obesity | pro-opiomelanocortin satiety | obesity Prader-Willi syndrome
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article